In the non–small cell lung cancer space, identifying the appropriate candidate to receive perioperative approaches, such as neoadjuvant or adjuvant therapy, remains the clinical objective.
Precision medicine has shown great potential to improve treatment outcomes and prolong survival of patients with lung cancer, as biomarker-driven therapies continue to extend their reach in this space.According to International Association for the Study of Lung Cancer, more than half of patients with lung cancer have tumors that harbor potentially actionable driver mutations. Therapies targeting